Skip to main content
Signal8
Launch Terminal

Vanda Pharmaceuticals Inc. (VNDA)

Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Vanda Pharmaceuticals Inc. logo

Vanda Pharmaceuticals Inc.

NASDAQ:VNDAHealthcare
-6.42%$3.79
AH$3.83+1.06%vs close
Mkt Cap$229.18M
Float57.64M
O/S60.47M
Vol
$ Vol
RVOL
Inst Own81.7%
SI14.4%
Earnings
Dilution
Vanda Pharmaceuticals Inc. logoNASDAQ:VNDA$3.79-6.42%
Upcoming Catalysts
Phase Distribution
82 lead-sponsored trials·18 active·54 completed
Phase 119
Phase 1/22
Phase 221
Phase 2/32
Phase 330
Phase 42
Not applicable6
(3 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Completed

    Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™)

    tasimelteon 20 mg capsule, tasimelteon 2 mg I.V.

    Non-24-Hour-Sleep-Wake Disorder

    Enrollment
    14
    Start
    May 2014
    Primary Completion
    May 2014
    Completion
    May 2014
    NCT02130999
  • Phase 4
    Recruiting

    Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

    Iloperidone

    Schizophrenia, Bipolar I Disorder

    Enrollment
    100
    Start
    May 2023
    Primary Completion
    Dec 2028est.
    Completion
    Dec 2028est.
    NCT05648591
  • Phase 3
    Completed

    Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia

    Iloperidone, Ziprasidone

    Schizophrenia

    Enrollment
    593
    Start
    Nov 2005
    Primary Completion
    Sep 2006
    Completion
    Mar 2007
    NCT00254202
  • Phase 3
    Completed

    VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia

    20 mg VEC-162, 50 mg VEC-162

    Insomnia

    Enrollment
    411
    Start
    Feb 2006
    Primary Completion
    Aug 2006
    Completion
    Aug 2006
    NCT00291187
  • Phase 3
    Completed

    VEC-162 Study in Adult Patients With Primary Insomnia

    VEC-162 20 mg, Placebo

    Primary Insomnia

    Enrollment
    322
    Start
    Nov 2007
    Primary Completion
    Feb 2008
    Completion
    Jun 2008
    NCT00548340
  • Phase 3
    Completed

    Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder

    tasimelteon, Placebo

    Non-24-Hour Sleep-Wake Disorder

    Enrollment
    136
    Start
    Aug 2010
    Primary Completion
    Nov 2012
    Completion
    Nov 2012
    NCT01163032
  • Phase 3
    Unknown status

    Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception

    tasimelteon

    Non 24 Hour Sleep Wake Disorder

    Enrollment
    140
    Start
    Oct 2010
    Primary Completion
    Dec 2024est.
    Completion
    Dec 2024est.
    NCT01218789
  • Phase 3
    Completed

    Relapse Prevention Study in Patients With Schizophrenia

    Iloperidone, Placebo

    Schizophrenia

    Enrollment
    635
    Start
    Feb 2011
    Primary Completion
    Mar 2014
    Completion
    Mar 2015
    NCT01291511
  • Phase 3
    Completed

    Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

    tasimelteon

    Non-24-Hour Sleep-Wake Disorder

    Enrollment
    200
    Start
    Oct 2011
    Primary Completion
    Jan 2015
    Completion
    Jan 2015
    NCT01429116
  • Phase 3
    Completed

    Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder

    tasimelteon, Placebo

    Non-24-Hour Sleep-Wake Disorder

    Enrollment
    20
    Start
    Sep 2011
    Primary Completion
    Dec 2012
    Completion
    Dec 2012
    NCT01430754
  • Phase 3
    Completed

    Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type Insomnia

    Tasimelteon, Placebo

    Jet Lag Type Insomnia

    Enrollment
    320
    Start
    Oct 2017
    Primary Completion
    Mar 2018
    Completion
    Mar 2018
    NCT03373201
  • Phase 3
    Completed

    Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)

    Tradipitant, Placebo

    Atopic Dermatitis

    Enrollment
    375
    Start
    Jul 2018
    Primary Completion
    Dec 2019
    Completion
    Dec 2019
    NCT03568331
  • Phase 3
    Completed

    Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis

    Tradipitant, Placebo

    Idiopathic Gastroparesis, Diabetic Gastroparesis +1

    Enrollment
    979
    Start
    Aug 2019
    Primary Completion
    Feb 2025
    Completion
    Feb 2025
    NCT04028492
  • Phase 3
    Terminated

    Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)

    Tradipitant, Placebo

    Atopic Dermatitis

    Enrollment
    87
    Start
    Oct 2019
    Primary Completion
    Oct 2020
    Completion
    Oct 2020
    NCT04140695
  • Phase 3
    Enrolling by invitation

    ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection

    Tradipitant, Placebo

    Coronavirus Infection

    Enrollment
    300
    Start
    Apr 2020
    Primary Completion
    Aug 2020est.
    Completion
    Aug 2020est.
    NCT04326426
  • Phase 3
    Completed

    Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness

    Tradipitant, Placebo

    Motion Sickness

    Enrollment
    366
    Start
    Nov 2021
    Primary Completion
    Apr 2023
    Completion
    Apr 2023
    NCT04327661
  • Phase 3
    Completed

    Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)

    Tasimelteon, Placebo

    Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm +1

    Enrollment
    43
    Start
    Dec 2020
    Primary Completion
    Sep 2026
    Completion
    Sep 2026
    NCT04652882
  • Phase 3
    Completed

    Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder

    Iloperidone, Iloperidone Placebo

    Bipolar I Disorder

    Enrollment
    417
    Start
    Mar 2021
    Primary Completion
    Sep 2022
    Completion
    Aug 2023
    NCT04819776
  • Phase 3
    Completed

    Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP

    750 mg Imsidolimab, 300 mg Imsidolimab

    Generalized Pustular Psoriasis

    Enrollment
    45
    Start
    Apr 2022
    Primary Completion
    Aug 2023
    Completion
    Aug 2023
    NCT05352893
  • Phase 3
    Unknown status

    Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances

    Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension

    Autism Spectrum Disorder, Sleep Disorder +2

    Enrollment
    100
    Start
    Jul 2021
    Primary Completion
    Jul 2025est.
    Completion
    Jul 2025est.
    NCT05361707
  • Phase 3
    Terminated

    Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP

    Double-blind 200 mg imsidolimab, Open-label 200 mg imsidolimab

    Generalized Pustular Psoriasis

    Enrollment
    42
    Start
    Apr 2022
    Primary Completion
    Jul 2024
    Completion
    Jul 2024
    NCT05366855
  • Phase 3
    Completed

    Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness

    Tradipitant, Placebo

    Motion Sickness

    Enrollment
    316
    Start
    Sep 2023
    Primary Completion
    Apr 2024
    Completion
    Apr 2024
    NCT05903924
  • Phase 3
    Active, not recruiting

    Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness

    Tradipitant

    Motion Sickness

    Enrollment
    705
    Start
    Feb 2023
    Primary Completion
    Sep 2027est.
    Completion
    Dec 2027est.
    NCT06138613
  • Phase 3
    Recruiting

    Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant

    Tasimelteon, Placebo

    Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm +2

    Enrollment
    60
    Start
    Oct 2024
    Primary Completion
    Jun 2025est.
    Completion
    Jun 2025est.
    NCT06701396
  • Phase 3
    Recruiting

    Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

    Milsaperidone, Placebo

    Major Depressive Disorder (MDD)

    Enrollment
    500
    Start
    Mar 2025
    Primary Completion
    Mar 2028est.
    Completion
    Mar 2028est.
    NCT06830044

1-25 of 82

Search ClinicalTrials.gov for “Vanda Pharmaceuticals”